Reportstack

Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

 

Naperville, IL -- (ReleaseWire) -- 03/10/2014 -- Reportstack, provider of premium market research reports announces the addition of Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis market report to its offering
The report entitled „Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis“  is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms. Business deal activities in form of acquisitions, licensing and collaboration agreements and joint ventures between pharma, biotech and the service industry serve to identify those technologies of interest for stakeholders in the ADC industry.

The report was built from the bottom-up by first elaborating Company Profiles from information retrieved from La Merie‘ proprietary antibody-drug conjugate database, scientific literature and abstracts, company press releases, company presentations, financial disclosures, clinical trials databases and company websites. A structured analysis was performed for the ADC pipeline, for stakeholders of the ADC industry, for state-of-the art and emerging ADC technologies, for the ADC manufacturing and service industry, and business activities. The report identifies trends for those ADC technologies (target, antibody, drug, linker and conjugation systems) which are of interest for the industry.

The report includes in the Addendum a tabulated Competitor Analysis and lists all relevant business transactions of the last two to three years.

Spefically, the ADC pipeline analysis describes preclinical, non-clinical and clinical ADC projects and R&D programs. It evaluates the ADC targets in relation to drug and linker systems, and also investigates the clinical success and reasons for failures of antibody-drug conjugates.

The stakeholder analysis compares companies with their peers in the respective group of development, technology and manufacturing companies and further categorizes them within the respective group to find out their competitive situation.

The analysis pays special attention to the importance of target selection, to emerging trends of new targeting moieties beyond full-length, canonical antibodies, to the expansion of the use of ADCs in non-cancer indications, to the opportunities arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs.

Crticial issues of ADCs, such as therapeutic window, druggable targets, manufacturing and financing are addressed and opportunities outlined.

Who will benefit from the report:

Investors

Business developers

Licensing managers

Technology officers

R&D Management

Business & Competitive Intelligence Analysts

Scientific Analysts

R&D Planning

Portfolio Managers

What will you find in the report?

Company profiles of ADC stakeholders

ADC drug profiles

ADC business agreements

ADC pipeline description and analysis

Clinical attrition rate of ADCs and reasons for failure

ADC target description and analysis

Current and future drugs, linkers and conjugation systems

Industry preferences for drugs and linkers

Alternative targeting moieties

New uses of ADCs and immunoconjugates

CMOs for manufacturing of ADCs

Competitors in development, technology or manufacturing

Commercial value of ADC products and technologies

Companies mentioned in the report

Abbott Contract Manufacturing

AbbVie

AbGenomics

Ablynx

ACES Pharma

ADC Therapeutics

Adcanced Proteome Therapeutics

Aeterna Zentaris

Affinicon

Albany Molecular Research Inc (AMRI)

Allozyne

Ambrx

Amgen

Amunix

Arrowhead Research

Astellas Pharma

AstraZeneca

Auven Therapeutics

Baxter BioPharma Solutions

Bayer HealthCare Pharmaceuticals

BIND Therapeutics

Biotecnol

Biotest

Bristol-Myers Squibb

BSP Pharmaceuticals

Carbogen Amcis

Catalent Biologics

Celgene

Celldex Therapeutics

Centrose

Coldstream Laboratories

Concortis Biosystems

CytomX

Daiichi Sankyo

Eli Lilly

Endo Pharmaceuticals

Esperance Pharmaceuticals

Evonik Industries

f-star

Fujifilm Diosynth Biotechnologies

Genmab

GlaxoSmithKline

Glykos

Goodwin Biotechnology

Wilex (Heidelberg Pharma)

Helix Biopharma

Heraeus

Igenica

Immune Pharmaceuticals

ImmunoGen

Immunomedics

Innate Pharma

Intellect Neurosciences

Janssen Research & Development

Lonza

Macrogenics

Meditope Biosciences

Menarini

Merck

Mersana Therapeutics

Molecular Partners

Nerviano Medical Sciences

Novartis

Novasep

Oncomatrix

Oxford BioTherapeutics

Pfizer

Philogen

Photobiotics

Phylogica

Pierre Fabre Group

Pierre Fabre Medicament Production

Piramal

Polytherics

Progenics Pharmaceuticals

Quanta Biodesign

Redwood Biodesign

Roche

Sanofi

Seattle Genetics

Serina Therapeutics

Shire

Sigma Aldrich SAFC

Sorrento Therapeutics

Spirogen

Stem CentRx

Sutro Biopharma

SynAffix

Synthon Biopharmaceuticals

Takeda Pharmaceutical

The Chemistry Research Solution

TUBE Pharma

University of California San Diego

WuXi PharmaTech

Zhejiang Medicine

Zymeworks

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/151312/antibody-drug-conjugates-2014-a-business-technology-pipeline-analysis.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###